Joseph Stringer
Stock Analyst at Needham
(4.87)
# 354
Out of 5,078 analysts
626
Total ratings
46.2%
Success rate
23.3%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Initiated: Buy | $8 | $3.45 | +131.88% | 1 | Oct 16, 2026 | |
| PCVX Vaxcyte | Rated: Buy | $110 → $122 | $65.27 | +86.92% | 44 | Oct 5, 2026 | |
| STTK Shattuck Labs | Rated: Buy | $17 → $19 | $5.53 | +243.58% | 7 | Oct 2, 2026 | |
| VIR Vir Biotechnology | Reiterated: Buy | $18 | $10.47 | +71.92% | 48 | Sep 28, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $86 | $44.12 | +94.92% | 47 | Sep 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $357 | $234.03 | +52.54% | 49 | Sep 17, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $35 | $5.35 | +554.21% | 8 | Sep 14, 2026 | |
| IFRX InflaRx | Initiated Coverage: Buy | $8 | $1.44 | +455.56% | 1 | Sep 14, 2026 | |
| MRNA Moderna | Reiterated: Hold | n/a | $236.50 | - | 44 | Aug 19, 2026 | |
| ANNX Annexon | Reiterated: Buy | $25 | $3.60 | +594.44% | 39 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.9724 | - | 34 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 | $157.37 | +8.03% | 31 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 | $87.97 | +47.78% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $24.61 | +62.54% | 46 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $508.75 | - | 33 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $22 | $7.50 | +193.33% | 75 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.65 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.07 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $19.71 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $136.95 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $51.52 | n/a | 2 | Apr 28, 2021 |
Camp4 Therapeutics
Oct 16, 2026
Initiated: Buy
Price Target: $8
Current: $3.45
Upside: +131.88%
Vaxcyte
Oct 5, 2026
Rated: Buy
Price Target: $110 → $122
Current: $65.27
Upside: +86.92%
Shattuck Labs
Oct 2, 2026
Rated: Buy
Price Target: $17 → $19
Current: $5.53
Upside: +243.58%
Vir Biotechnology
Sep 28, 2026
Reiterated: Buy
Price Target: $18
Current: $10.47
Upside: +71.92%
Ionis Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: $86
Current: $44.12
Upside: +94.92%
Alnylam Pharmaceuticals
Sep 17, 2026
Reiterated: Buy
Price Target: $357
Current: $234.03
Upside: +52.54%
BioAge Labs
Sep 14, 2026
Reiterated: Buy
Price Target: $35
Current: $5.35
Upside: +554.21%
InflaRx
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.44
Upside: +455.56%
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $236.50
Upside: -
Annexon
Aug 12, 2026
Reiterated: Buy
Price Target: $25
Current: $3.60
Upside: +594.44%
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.9724
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $170
Current: $157.37
Upside: +8.03%
Aug 4, 2026
Reiterated: Buy
Price Target: $130
Current: $87.97
Upside: +47.78%
Aug 4, 2026
Reiterated: Buy
Price Target: $40
Current: $24.61
Upside: +62.54%
Aug 4, 2026
Reiterated: Hold
Price Target: n/a
Current: $508.75
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: $28 → $22
Current: $7.50
Upside: +193.33%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $1.65
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $1.07
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $19.71
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $136.95
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $51.52
Upside: n/a